- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 2
The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of April 2, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 2.
Number 5: A recently published descriptive review finds a significant time lag between the approval of biosimilar infliximab and its acceptance in Irish hospitals.
Number 4: The Senate Homeland Security and Government Affairs Committee has released a report on prescription drug price increases that affect drugs that seniors use most. According to the report, drug prices rise at approximately 10 times the rate of inflation.
Number 3: CMS will lower the maximum co-payment amount for low-income subsidy beneficiaries for biosimilars.
Number 2: Samsung Bioepis and Biogen have reached a settlement with AbbVie that will allow the biosimilar adalimumab, Imraldi, to launch in Europe later this year.
Number 1: Celltrion has announced that the FDA has issued Complete Response Letters for 2 of its proposed biosimilar products.
Also this week, expert contributor Sonia T. Oskouei explains 9 key facts about biosimilar interchangeability in the United States.
Finally, last week, our e-newsletter asked whether you think one payer’s recent decision not to undertake a nonmedical switch to a biosimilar is good news for patients.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
Top 5 Most-Read Regulatory Articles of 2024
December 25th 2024In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
